| In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues: |
| BayMedica | 2.3 | 1.0 | 0.3 | 0.5 | 0.3 | 0.3 | | |
| Other | 1.4 | | | | | | | |
| Revenues | 3.7 | 1.0 | 0.3 | 0.5 | 0.3 | 0.3 | 0.0 | 0.9 |
| Revenue growth [+] | 614.3% | 234.0% | | -41.5% | -29.2% | -4.2% | | |
| BayMedica | 349.0% | 234.0% | | | | | | |
| Cost of goods sold | 1.0 | 0.8 | 0.2 | 0.3 | 0.1 | 0.2 | 0.1 | 0.0 |
| Gross profit | 2.7 | 0.2 | 0.1 | 0.2 | 0.2 | 0.1 | -0.1 | 0.9 |
| Gross margin | 72.6% | 18.6% | 26.7% | 48.5% | 58.9% | 42.1% | | 100.0% |
| Selling, general and administrative [+] | 1.8 | 1.4 | 1.6 | 2.0 | 1.9 | 1.8 | 1.4 | 1.6 |
| General and administrative | 1.8 | 1.4 | 1.6 | 2.0 | 1.9 | 1.8 | 1.4 | 1.6 |
| Research and development | 0.6 | 0.9 | 1.4 | 1.5 | 1.8 | 2.5 | 1.5 | 1.7 |
| Other operating expenses | 0.1 | 0.0 | 0.7 | 1.1 | 0.0 | 0.0 | 0.0 | 0.8 |
| EBITDA [+] | 0.2 | -2.1 | -3.5 | -4.4 | -3.5 | -4.3 | -2.9 | -3.2 |
| EBITDA growth | -104.4% | -39.2% | 19.4% | 37.3% | 13.2% | 136.6% | 82.6% | 113.3% |
| EBITDA margin | 5.3% | -203.1% | -1098.2% | -850.3% | -1115.5% | -1605.6% | | -361.9% |
| Depreciation | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITA | 0.1 | -2.1 | -3.5 | -4.4 | -3.5 | -4.3 | -3.0 | -3.2 |
| EBITA margin | 3.8% | -204.1% | -1100.7% | -860.8% | -1118.0% | -1607.9% | | -362.5% |
| Amortization of intangibles | | 0.0 | 0.0 | | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | 0.1 | -2.2 | -3.6 | -4.4 | -3.5 | -4.3 | -3.0 | -3.2 |
| EBIT growth | -103.2% | -38.7% | 19.9% | 37.8% | 14.0% | 134.6% | 81.3% | 111.5% |
| EBIT margin | 3.8% | -208.0% | -1113.5% | -860.8% | -1132.7% | -1624.4% | | -365.2% |
| Non-recurring items | 0.6 | | | 3.5 | | | | |
| Interest income | 0.1 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest income | 0.1 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | 0.0 | 0.0 | 0.0 | 0.0 | | 0.0 | 0.0 | 0.0 |
| Gain (loss) on foreign currency transactions | 0.0 | | 0.0 | 0.0 | | 0.0 | 0.0 | 0.0 |
| Other non-operating income | | | | | | 0.0 | | |
| Other | | | | | | 0.0 | | |
| Pre-tax income | -0.3 | -2.0 | -3.5 | -7.9 | -3.5 | -4.3 | -3.0 | -3.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -0.3 | -2.0 | -3.5 | -7.9 | -3.5 | -4.3 | -3.0 | -3.3 |
| Net margin | -9.2% | -193.2% | -1094.2% | -1528.9% | -1122.7% | -1615.6% | | -370.0% |
| |
| Basic EPS [+] | ($0.14) | ($0.60) | ($4.06) | ($14.03) | ($6.14) | ($0.31) | ($6.17) | ($12.12) |
| Growth | -99.0% | -90.2% | -34.2% | 15.7% | 1394.5% | -16.0% | 1913.2% | 3816.3% |
| Diluted EPS [+] | ($0.14) | ($0.60) | ($4.06) | ($14.03) | ($6.14) | ($0.31) | ($6.17) | ($12.12) |
| Growth | -99.0% | -90.2% | -34.2% | 15.7% | 1394.5% | -16.0% | 1913.2% | 3816.3% |
| |
| Shares outstanding (basic) [+] | 2.4 | 3.3 | 0.9 | 0.6 | 0.6 | 13.8 | 0.5 | 0.3 |
| Growth | 336.6% | 488.0% | 79.6% | 108.6% | -92.5% | 127.3% | -90.8% | -94.9% |
| Shares outstanding (diluted) [+] | 2.4 | 3.3 | 0.9 | 0.6 | 0.6 | 13.8 | 0.5 | 0.3 |
| Growth | 336.6% | 488.0% | 79.6% | 108.6% | -92.5% | 127.3% | -90.8% | -94.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |